Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05612100 · ClinicalTrials.gov registry record
Endocrine Therapy-Induced Alopecia in Postmenopausal and Premenopausal Female Breast Cancer Patients
A clinical trial of Breast Carcinoma, sponsored by Mayo Clinic.
- Recruiting
- Registry status
- 170
- Enrollment target
- 20
- Study locations
NCT05612100: Recruiting study of Breast Carcinoma, sponsored by Mayo Clinic.
NCT05612100 is a study of Breast Carcinoma that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 170 participants, below the 769-participant average among 106 other Breast Carcinoma trials with a reported enrollment target (78% lower). The trial reports 20 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05612100, a study of Breast Carcinoma, is actively recruiting participants, sponsored by Mayo Clinic.
- RECRUITING
- Registry status
- 170 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study evaluates endocrine therapy-induced alopecia among postmenopausal and premenopausal female patients with breast cancer. Alopecia is one of the most feared side effects of cancer-directed therapy, causing distress in women starting treatment for breast cancer. While alopecia is a well-known side effect of many chemotherapy drugs, it has also been reported by women undergoing endocrine therapy. Despite the frequent reports of alopecia related to endocrine therapy, hair loss is rarely reported as a side effect of endocrine therapy and the exact characterization of alopecia is not well understood. By having postmenopausal and premenopausal breast cancer patients describe their hair loss symptoms experienced while undergoing endocrine therapy, researchers may be able to better characterize the incidence, timing, duration, and severity of alopecia and whether the different types of endocrine therapy cause more or less trouble in this regard.
Primary Outcome
Exact 95% confidence intervals will be created within each cohort and compared graphically using forest plots. Plots of alopecia incidence rates and severity will be plotted over time by cohort.
Conditions Studied
Interventions
- OTHER Survey Administration
- OTHER Questionnaire Administration
- OTHER Electronic Health Record Review
Study Locations (20)
Minnesota
- Mayo Clinic Health System in Albert Lea - Albert Lea
- Essentia Health Baxter Clinic - Baxter
- Sanford Joe Lueken Cancer Center - Bemidji
- Essentia Health Saint Joseph's Medical Center - Brainerd
- Essentia Health - Deer River Clinic - Deer River
- Essentia Health Saint Mary's - Detroit Lakes Clinic - Detroit Lakes
- Essentia Health Cancer Center - Duluth
- Essentia Health Ely Clinic - Ely
- Essentia Health - Fosston - Fosston
- Fairview Grand Itasca Clinic & Hospital - Grand Rapids
- Essentia Health Hibbing Clinic - Hibbing
- Fairview Range Medical Center - Hibbing
- Essentia Health - International Falls Clinic - International Falls
- Mayo Clinic Health Systems-Mankato - Mankato
- MMCORC CentraCare Monticello Cancer Center - Monticello
- Essentia Health Moose Lake - Moose Lake
- Essentia Health - Park Rapids - Park Rapids
- Fairview Northland Medical Center - Princeton
- Mayo Clinic in Rochester - Rochester
- Essentia Health Sandstone - Sandstone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 170 participants |
| Start Date | 2022-07-06 |
| Est. Completion | 2028-06-30 |
What NCT05612100 shows while recruiting
NCT05612100 is an observational study that tracks outcomes without assigning an intervention. The registered 170 participants enrollment target is mid-sized for trials with a published cap, below the 769-participant average among 106 other Breast Carcinoma trials with a reported enrollment target (78% lower).
The record links to 1 condition, with Breast Carcinoma appearing as the primary indexed condition, and to 3 interventions - of which Survey Administration is the first listed.
NCT05612100 names 20 study sites across 1 states, led by Minnesota.
Frequently Asked Questions
What is clinical trial NCT05612100 about?
NCT05612100 is a clinical study titled "Endocrine Therapy-Induced Alopecia in Postmenopausal and Premenopausal Female Breast Cancer Patients". This study evaluates endocrine therapy-induced alopecia among postmenopausal and premenopausal female patients with breast cancer. Alopecia is one of the most feared side effects of cancer-directed therapy, causing distress in women starting treatment for breast cancer. While alopecia is a well-know...
What is the current status of trial NCT05612100?
This trial is currently recruiting. The enrollment target is 170 participants. The study started on 2022-07-06. Estimated completion is 2028-06-30.
What conditions does trial NCT05612100 study?
This clinical trial studies the following conditions: Breast Carcinoma.
What interventions are being tested in trial NCT05612100?
The interventions under investigation include: Survey Administration (OTHER), Questionnaire Administration (OTHER), Electronic Health Record Review (OTHER).
Who is sponsoring clinical trial NCT05612100?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05612100 being conducted?
This trial has 20 study locations across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05612100's enrollment target sits among peer trials
170 43rd of 106 higher than 64 of 106 other Breast Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Surviving Daily Life
RECRUITING
-
Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Congestive Heart Failure Receiving Therapy for Breast Cancer
RECRUITING
-
Hypofractionated Radiotherapy Before or After Breast Surgery for Treatment of Patients With Non-Metastatic Breast Cancer
RECRUITING · Phase 2
-
Ultra-hypofractionated Whole Breast Irradiation With Lumpectomy Cavity Boost for the Treatment of Stage I-III Breast Cancer
RECRUITING · Phase 2
-
Breast Cancer Screening Adherence for Women at Moderate Risk for Breast Cancer
RECRUITING
-
Impact of Dietary Inflammatory Potential on Breast Cancer Risk
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02016430 · 170 participants · NA
Gut Flora Metabolite Reduction After Dietary Intervention (GRADY)
- NCT02621021 · 170 participants · Phase 2
A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab
- NCT04094701 · 170 participants · NA
Hip Arthroscopy Postoperative Opioid Demands
- NCT04166409 · 170 participants · Phase 3
A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI